{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:42:17Z","timestamp":1777999337927,"version":"3.51.4"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10792-013-9788-5","type":"journal-article","created":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T08:01:24Z","timestamp":1369987284000},"page":"365-381","source":"Crossref","is-referenced-by-count":41,"title":["Current and future treatments for Beh\u00e7et\u2019s uveitis: road to remission"],"prefix":"10.1007","volume":"34","author":[{"given":"Marina","family":"Mesquida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Molins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Lloren\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Victoria","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Ad\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,1]]},"reference":[{"key":"9788_CR1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.preteyeres.2007.09.002","volume":"27","author":"CM Deuter","year":"2008","unstructured":"Deuter CM, K\u00f6tter I, Wallace GR, Murray PI, St\u00fcbiger N, Zierhut M (2008) Beh\u00e7et\u2019s disease: ocular effects and treatment. Prog Retin Eye Res 27:111\u2013136","journal-title":"Prog Retin Eye Res"},{"key":"9788_CR2","first-page":"1152","volume":"105","author":"H Beh\u00e7et","year":"1937","unstructured":"Beh\u00e7et H (1937) \u00dcberrezidivierendeaphth\u00f6sedurchein Virus verursachte Geschw\u00fcre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 105:1152\u20131157","journal-title":"Dermatol Wochenschr"},{"key":"9788_CR3","first-page":"1078","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease (1990) Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 335:1078\u20131080","journal-title":"Lancet"},{"key":"9788_CR4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09273948.2012.723112","volume":"20","author":"M Khairallah","year":"2012","unstructured":"Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH (2012) Epidemiology of Beh\u00e7et disease. Ocul Immunol Inflamm 20:324\u2013335","journal-title":"Ocul Immunol Inflamm"},{"key":"9788_CR5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1046\/j.1365-4362.2003.01893.x","volume":"42","author":"G Azizerli","year":"2003","unstructured":"Azizerli G, Kose AA, Sarica R et al (2003) Prevalence of Beh\u00e7et\u2019s disease in Istanbul, Turkey. Int J Dermatol 42:803\u2013806","journal-title":"Int J Dermatol"},{"key":"9788_CR6","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s10067-010-1491-6","volume":"29","author":"VD Kapsimali","year":"2010","unstructured":"Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG (2010) Etiopathogenesis of Beh\u00e7et\u2019s disease with emphasis on the role of immunological aberrations. Clin Rheumatol 29:1211\u20131216","journal-title":"Clin Rheumatol"},{"key":"9788_CR7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.autrev.2009.10.005","volume":"9","author":"C Mendoza-Pinto","year":"2010","unstructured":"Mendoza-Pinto C, Garc\u00eda-Carrasco M, Jim\u00e9nez-Hern\u00e1ndez M et al (2010) Etiopathogenesis of Behcet\u2019s disease. Autoimmun Rev 9:241\u2013245","journal-title":"Autoimmun Rev"},{"key":"9788_CR8","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/rheumatology\/ker428","volume":"51","author":"C Maldini","year":"2012","unstructured":"Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A (2012) Relationships of HLA-B51 or B5 genotype with Behcet\u2019s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxf) 51:887\u2013900","journal-title":"Rheumatology (Oxf)"},{"key":"9788_CR9","doi-asserted-by":"crossref","unstructured":"Hazirolan D, St\u00fcbiger N, Pleyer U (2012) Light on the Horizont: biologicals in Beh\u00e7et uveitis. Acta Ophthalmol. doi: 10.1111\/j.1755-3768.2011.02348.x","DOI":"10.1111\/j.1755-3768.2011.02348.x"},{"key":"9788_CR10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2011.12.005","volume":"11","author":"ZY Zhou","year":"2012","unstructured":"Zhou ZY, Chen SL, Shen N, Lu Y (2012) Cytokines and Behcet\u2019s disease. Autoimmun Rev 11:699\u2013704","journal-title":"Autoimmun Rev"},{"key":"9788_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","volume":"31","author":"K Hamzaoui","year":"2002","unstructured":"Hamzaoui K, Hamzaoui A, Guemira F et al (2002) Cytokine profile in Beh\u00e7et\u2019s disease patients. Relationship with disease activity. Scand J Rheumatol 31:205\u2013210","journal-title":"Scand J Rheumatol"},{"key":"9788_CR12","first-page":"663","volume-title":"Ocular infection and immunity","author":"M Mochizuki","year":"1996","unstructured":"Mochizuki M, Akduman L, Nussenblatt RB (1996) Beh\u00e7et\u2019s disease. In: Pepose JS, Holland GN, Wilhelmus KR (eds) Ocular infection and immunity. Mosby, St. Louis, pp 663\u2013675"},{"key":"9788_CR13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10067-010-1430-6","volume":"29","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shahram F, Chams-Davatchi C et al (2010) Beh\u00e7et\u2019s disease: from East to West. Clin Rheumatol 29:823\u2013833","journal-title":"Clin Rheumatol"},{"key":"9788_CR14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol 138:373\u2013380","journal-title":"Am J Ophthalmol"},{"key":"9788_CR15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ophtha.2007.04.056","volume":"115","author":"P Yang","year":"2008","unstructured":"Yang P, Fang W, Meng Q et al (2008) Clinical features of Chinese patients with Beh\u00e7et\u2019s disease. Ophthalmology 115:312\u2013318","journal-title":"Ophthalmology"},{"key":"9788_CR16","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","volume":"91","author":"N Kitaichi","year":"2007","unstructured":"Kitaichi N, Miyazaki A, Stanford MR et al (2007) Ocular features of Beh\u00e7et\u2019s disease: an international collaborative study. Br J Ophthalmol 91:1579\u20131582","journal-title":"Br J Ophthalmol"},{"key":"9788_CR17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/09273948.2011.630550","volume":"20","author":"OA Saleh","year":"2012","unstructured":"Saleh OA, Birnbaum AD, Tessler HH et al (2012) Beh\u00e7et uveitis in the American Midwest. Ocul Immunol Inflamm 20:12\u201317","journal-title":"Ocul Immunol Inflamm"},{"key":"9788_CR18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","volume":"50","author":"N Markomichelakis","year":"2011","unstructured":"Markomichelakis N, Delicha E, Masselos S et al (2011) A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et\u2019s disease: a comparative 4-week study. Rheumatology (Oxf) 50:593\u2013597","journal-title":"Rheumatology (Oxf)"},{"key":"9788_CR19","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs. N Engl J Med 353:1711\u20131723","journal-title":"N Engl J Med"},{"key":"9788_CR20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000055585","volume":"32","author":"T Tanaka","year":"2000","unstructured":"Tanaka T, Suzuki J, Yamakawa N, Usui M (2000) Steroid sensitivity and postoperative course of seven patients with Beh\u00e7et\u2019s disease. Ophthalmic Res 32:41\u201343","journal-title":"Ophthalmic Res"},{"key":"9788_CR21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","volume":"152","author":"SR Taylor","year":"2011","unstructured":"Taylor SR, Singh J, Menezo V et al (2011) Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol 152:1059\u20131066","journal-title":"Am J Ophthalmol"},{"key":"9788_CR22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/rheumatology\/26.4.285","volume":"26","author":"AI Binder","year":"1987","unstructured":"Binder AI, Graham EM, Sanders MD, Dinning W, James DG, Denman AM (1987) Cyclosporin A in the treatment of severe Behcet\u2019s uveitis. Br J Rheumatol 26:285\u2013291","journal-title":"Br J Rheumatol"},{"key":"9788_CR23","first-page":"136","volume":"20","author":"D BenEzra","year":"1988","unstructured":"BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et\u2019s syndrome. Transplant Proc 20:136\u2013143","journal-title":"Transplant Proc"},{"key":"9788_CR24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","volume":"76","author":"Y Ozyazgan","year":"1992","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H et al (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet\u2019s syndrome: a single masked trial. Br J Ophthalmol 76:241\u2013243","journal-title":"Br J Ophthalmol"},{"key":"9788_CR25","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","volume":"106","author":"S Kotake","year":"1999","unstructured":"Kotake S, Higashi K, Yoshikawa K et al (1999) Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology 106:586\u2013589","journal-title":"Ophthalmology"},{"key":"9788_CR26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00002281-200101000-00004","volume":"13","author":"H Yazici","year":"2001","unstructured":"Yazici H, Yurdakul S, Hamuryudan V (2001) Behcet disease. Curr Opin Rheumatol 13:18\u201322","journal-title":"Curr Opin Rheumatol"},{"key":"9788_CR27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1076\/ocii.6.2.101.4051","volume":"6","author":"DJ Kilmartin","year":"1998","unstructured":"Kilmartin DJ, Forrester JV, Dick AD (1998) Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 6:101\u2013109","journal-title":"Ocul Immunol Inflamm"},{"key":"9788_CR28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","volume":"123","author":"CC Murphy","year":"2005","unstructured":"Murphy CC, Greiner K, Plskova J et al (2005) Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 123:634\u2013641","journal-title":"Arch Ophthalmol"},{"key":"9788_CR29","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2165\/00003495-200363150-00002","volume":"63","author":"K Tanabe","year":"2003","unstructured":"Tanabe K (2003) Calcineurin inhibitors in renal transplantation: what is the best option? Drugs 63:1535\u20131548","journal-title":"Drugs"},{"key":"9788_CR30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behcet\u2019s syndrome. N Engl J Med 322:281\u2013285","journal-title":"N Engl J Med"},{"key":"9788_CR31","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/acr.20308","volume":"62","author":"D Saadoun","year":"2010","unstructured":"Saadoun D, Wechsler B, Terrada C et al (2010) Azathioprine in severe uveitis of Beh\u00e7et\u2019s disease. Arthritis Care Res (Hoboken) 62:1733\u20131738","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"9788_CR32","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","volume":"68","author":"G Hatemi","year":"2009","unstructured":"Hatemi G, Silman A, Bang D et al (2009) Management of Beh\u00e7et disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis 68:1528\u20131534","journal-title":"Ann Rheum Dis"},{"key":"9788_CR33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00417-009-1234-z","volume":"248","author":"T Kaburaki","year":"2010","unstructured":"Kaburaki T, Araki F, Takamoto M et al (2010) Best-corrected visual acuity and frequency of ocular attacks during the initial 10\u00a0years in patients with Beh\u00e7et\u2019s disease. Graefes Arch Clin Exp Ophthalmol 248:709\u2013714","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"9788_CR34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/09273940903072443","volume":"17","author":"SM Sharma","year":"2009","unstructured":"Sharma SM, Nestel AR, Lee RW, Dick AD (2009) Clinical review: anti-TNFalpha therapies in uveitis: perspective on 5\u00a0years of clinical experience. Ocul Immunol Inflamm 17(6):403\u2013414","journal-title":"Ocul Immunol Inflamm"},{"key":"9788_CR35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","volume":"23","author":"AN Theofilopoulos","year":"2005","unstructured":"Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha\/-beta) in immunity and autoimmunity. Annu Rev Immunol 23:307\u2013336","journal-title":"Annu Rev Immunol"},{"key":"9788_CR36","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/rheumatology\/keh311","volume":"43","author":"M Treusch","year":"2004","unstructured":"Treusch M, Vonthein R, Baur M et al (2004) Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet\u2019s disease. Rheumatology (Oxf) 43:1275\u20131282","journal-title":"Rheumatology (Oxf)"},{"key":"9788_CR37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.12968\/hmed.2008.69.10.31317","volume":"69","author":"DS Yang","year":"2008","unstructured":"Yang DS, Talylor SR, Lightman SL (2008) Interferon-alpha in the management of patients with Beh\u00e7et\u2019s disease. Br J Hosp Med (Lond) 69:575\u2013579","journal-title":"Br J Hosp Med (Lond)"},{"key":"9788_CR38","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","volume":"134","author":"CC Zouboulis","year":"1998","unstructured":"Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades\u2013Behcet disease with systemic interferon alfa. Arch Dermatol 134:1010\u20131016","journal-title":"Arch Dermatol"},{"key":"9788_CR39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","volume":"138","author":"E Alpsoy","year":"2002","unstructured":"Alpsoy E, Durusoy C, Yilmaz E et al (2002) Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138:467\u2013471","journal-title":"Arch Dermatol"},{"key":"9788_CR40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2010.115","volume":"6","author":"N Warde","year":"2010","unstructured":"Warde N (2010) Therapy: Beh\u00e7et uveitis: good results for IFN-alpha-2a. Nat Rev Rheumatol 6:437","journal-title":"Nat Rev Rheumatol"},{"key":"9788_CR41","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"CM Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, M\u00f6hle A et al (2010) Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease. Arthritis Rheum 62:2796\u20132805","journal-title":"Arthritis Rheum"},{"key":"9788_CR42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"I K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M, St\u00fcbiger N (2004) The use of interferon a in Behcet disease: review of the literature. Semin Arthritis Rheum 33:320\u2013335","journal-title":"Semin Arthritis Rheum"},{"key":"9788_CR43","first-page":"1437","volume":"84","author":"N St\u00fcbiger","year":"2000","unstructured":"St\u00fcbiger N, K\u00f6tter I, Zierhut M (2000) Complete regression of retinal neovascularisation after therapy with interferon alfa in Behcet\u2019s disease. Br J Ophthalmol 84:1437\u20131438","journal-title":"Br J Ophthalmol"},{"key":"9788_CR44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.preteyeres.2004.06.005","volume":"23","author":"AD Dick","year":"2004","unstructured":"Dick AD, Forrester JV, Liversidge J et al (2004) The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 23:617\u2013637","journal-title":"Prog Retin Eye Res"},{"key":"9788_CR45","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","volume":"139","author":"AM El-Asrar","year":"2011","unstructured":"El-Asrar AM, Struyf S, Kangave D et al (2011) Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol 139:177\u2013184","journal-title":"Clin Immunol"},{"key":"9788_CR46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2006.04.016","volume":"142","author":"JK Ahn","year":"2006","unstructured":"Ahn JK, Yu HG, Chung H, Park YG (2006) Intraocular cytokine environment in active Beh\u00e7et uveitis. Am J Ophthalmol 142:429\u2013434","journal-title":"Am J Ophthalmol"},{"key":"9788_CR47","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/eji.1830260510","volume":"26","author":"AD Dick","year":"1996","unstructured":"Dick AD, McMenamin PG, K\u00f6rner H, Scallon BJ, Ghrayeb J, Forrester JV et al (1996) Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol 26:1018\u20131025","journal-title":"Eur J Immunol"},{"key":"9788_CR48","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archopht.122.6.845","volume":"122","author":"CC Murphy","year":"2004","unstructured":"Murphy CC, Greiner K, Plskova J, Duncan L, Frost A, Isaacs JD et al (2004) Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 122:845\u2013851","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"9788_CR49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP (2011) Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum 41(1):61\u201370","journal-title":"Semin Arthritis Rheum"},{"key":"9788_CR50","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","volume":"140","author":"PP Sfikakis","year":"2004","unstructured":"Sfikakis PP, Kaklamanis PH, Elezoglou A et al (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades\u2013Behcet disease. Ann Intern Med 140:404\u2013406","journal-title":"Ann Intern Med"},{"key":"9788_CR51","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet\u2019s disease with refractory uveoretinitis. J Rheumatol 31:1362\u20131368","journal-title":"J Rheumatol"},{"key":"9788_CR52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Y Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H et al (2010) Comparison of infliximab versus cyclosporin during the initial 6-month treatment period in Beh\u00e7et disease. Br J Ophthalmol 94:284\u2013288","journal-title":"Br J Ophthalmol"},{"key":"9788_CR53","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is refractory to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease. An open-label trial. Arthritis Rheum 52:2478\u20132484","journal-title":"Arthritis Rheum"},{"issue":"5","key":"9788_CR54","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","volume":"130","author":"AA Okada","year":"2012","unstructured":"Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Beh\u00e7et\u2019s Disease Research Group Of Japan (2012) Multicenter study of infliximab for refractory uveoretinitis in Beh\u00e7et disease. Arch Ophthalmol 130(5):592\u2013598","journal-title":"Arch Ophthalmol"},{"key":"9788_CR55","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/09273948.2010.483314","volume":"18","author":"A Bawazeer","year":"2010","unstructured":"Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Beh\u00e7et disease. Ocul Immunol Inflamm 18:226\u2013232","journal-title":"Ocul Immunol Inflamm"},{"key":"9788_CR56","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","volume":"119","author":"M D\u00edaz-Llopis","year":"2012","unstructured":"D\u00edaz-Llopis M, Salom D, Garcia-de-Vicu\u00f1a C, Cordero-Coma M, Ortega G, Ortego N et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119:1575\u20131581","journal-title":"Ophthalmology"},{"key":"9788_CR57","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","volume":"51","author":"D Perra","year":"2012","unstructured":"Perra D, Alba MA, Callejas JL, Mesquida M, R\u00edos-Fern\u00e1ndez R, Ad\u00e1n A et al (2012) Adalimumab for the treatment of Behcet\u2019s disease: experience in 19 patients. Rheumatology (Oxf) 51:1825\u20131831","journal-title":"Rheumatology (Oxf)"},{"key":"9788_CR58","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","volume":"31","author":"K Takase","year":"2011","unstructured":"Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis. Rheumatol Int 31:243\u2013245","journal-title":"Rheumatol Int"},{"issue":"4 Suppl 67","key":"9788_CR59","first-page":"S93","volume":"29","author":"P Leccese","year":"2011","unstructured":"Leccese P, Latanza L, D\u2019Angelo S, Padula A, Olivieri I (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Beh\u00e7et\u2019s disease to infliximab. Clin Exp Rheumatol 29(4 Suppl 67):S93","journal-title":"Clin Exp Rheumatol"},{"key":"9788_CR60","doi-asserted-by":"crossref","first-page":"1892.e3","DOI":"10.1016\/j.ophtha.2011.05.019","volume":"118","author":"M Cordero-Coma","year":"2011","unstructured":"Cordero-Coma M, Salom D, D\u00edaz-Llopis M, L\u00f3pez-Prats MJ, Calleja S (2011) Golimumab for uveitis. Ophthalmology 118:1892.e3\u20131892.e4","journal-title":"Ophthalmology"},{"key":"9788_CR61","doi-asserted-by":"crossref","unstructured":"William M, Faez S, Papaliodis GN, Lobo AM (2012) Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2(4):231\u2013233","DOI":"10.1007\/s12348-012-0081-y"},{"key":"9788_CR62","doi-asserted-by":"crossref","unstructured":"Mesquida M, Hern\u00e1ndez MV, Lloren\u00e7 V, Pelegr\u00edn L, Espinosa G, Dick AD, et al (2012) Beh\u00e7et disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 21(2):160\u2013162","DOI":"10.3109\/09273948.2012.741744"},{"key":"9788_CR63","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.ophtha.2006.04.038","volume":"113","author":"A Galor","year":"2006","unstructured":"Galor A, Perez VL, Hammel JP, Lowder CY (2006) Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113:2137\u20132323","journal-title":"Ophthalmology"},{"key":"9788_CR64","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","volume":"46","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Beh\u00e7et\u2019s disease\u2014review and basis for recommendations. Rheumatology (Oxf) 46:736\u2013741","journal-title":"Rheumatology (Oxf)"},{"issue":"7","key":"9788_CR65","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"EB Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Wertheim MS et al (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123(7):903\u2013912","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"9788_CR66","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Niccoli","year":"2007","unstructured":"Niccoli L, Nannini C, Benucci M et al (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et\u2019s disease: a 24-month follow-up study. Rheumatology (Oxf) 46(7):1161\u20131164","journal-title":"Rheumatology (Oxf)"},{"issue":"5","key":"9788_CR67","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10792-010-9372-1","volume":"30","author":"A Ad\u00e1n","year":"2010","unstructured":"Ad\u00e1n A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, Sanmart\u00ed R (2010) Effects of infliximab in the treatment of refractory posterior uveitis of Beh\u00e7et\u2019s disease after withdrawal of infusions. Int Ophthalmol 30(5):577\u2013581","journal-title":"Int Ophthalmol"},{"key":"9788_CR68","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1167\/iovs.10-5916","volume":"52","author":"S Sugita","year":"2011","unstructured":"Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M (2011) Induction of regulatory T cells by infliximab in Behcet\u2019s disease. Investig Ophthalmol Vis Sci 52:476\u2013484","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"9788_CR69","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","volume":"91","author":"B Bodaghi","year":"2007","unstructured":"Bodaghi B, Gendron G, Wechsler B et al (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91:335\u2013339","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"9788_CR70","first-page":"1633","volume":"32","author":"I Kotter","year":"2005","unstructured":"Kotter I, Deuter C, Stubiger N, Zierhut M (2005) Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Beh\u00e7et\u2019s disease: focusing more on IFN. J Rheumatol 32(8):1633 (author reply 1634)","journal-title":"J Rheumatol"},{"issue":"5 Suppl 1","key":"9788_CR71","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","volume":"34","author":"I Nestorov","year":"2005","unstructured":"Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: How do they differ? Semin Arthritis Rheum 34(5 Suppl 1):12\u201318","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"9788_CR72","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","volume":"21","author":"B Mushtaq","year":"2007","unstructured":"Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Beh\u00e7et\u2019s disease. Eye (Lond) 21(6):824\u2013825","journal-title":"Eye (Lond)"},{"issue":"3","key":"9788_CR73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/09273948.2010.483314","volume":"18","author":"A Bawazeer","year":"2010","unstructured":"Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Beh\u00e7et disease. Ocul Immunol Inflamm 18(3):226\u2013232","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"9788_CR74","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","volume":"51","author":"D Perra","year":"2012","unstructured":"Perra D, Alba MA, Callejas JL, Mesquida M, R\u00edos-Fern\u00e1ndez R, Ad\u00e1n A, Ortego N, Cervera R, Espinosa G (2012) Adalimumab for the treatment of Behcet\u2019s disease: experience in 19 patients. Rheumatology (Oxf) 51(10):1825\u20131831","journal-title":"Rheumatology (Oxf)"},{"issue":"4 Suppl 67","key":"9788_CR75","first-page":"S54","volume":"29","author":"I Olivieri","year":"2011","unstructured":"Olivieri I, Leccese P, D\u2019Angelo S, Padula A, Nigro A, Palazzi C, Coniglio G, Latanza L (2011) Efficacy of adalimumab in patients with Beh\u00e7et\u2019s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 29(4 Suppl 67):S54\u2013S57","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"9788_CR76","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00296-009-1178-y","volume":"31","author":"K Takase","year":"2011","unstructured":"Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis. Rheumatol Int 31(2):243\u2013245","journal-title":"Rheumatol Int"},{"key":"9788_CR77","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/ard.2009.116319","volume":"69","author":"E Keystone","year":"2010","unstructured":"Keystone E, Genovese MC, Klareskog L et al (2010) Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 69:1129\u20131135","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"9788_CR78","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1136\/annrheumdis-2011-200956","volume":"71","author":"JS Smolen","year":"2012","unstructured":"Smolen JS, Kay J, Landew\u00e9 RB et al (2012) Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Dis 71(10):1671\u20131679","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"9788_CR79","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/ard.2009.116319","volume":"69","author":"E Keystone","year":"2010","unstructured":"Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, Pazdur J, Bae SC, Palmer W, Xu S, Rahman MU (2010) Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 69(6):1129\u20131135","journal-title":"Ann Rheum Dis"},{"issue":"9194","key":"9788_CR80","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932\u20131939","journal-title":"Lancet"},{"issue":"8","key":"9788_CR81","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11(8):633\u2013652","journal-title":"Nat Rev Drug Discov"},{"key":"9788_CR82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1568010053622894","volume":"4","author":"A G\u00fcl","year":"2005","unstructured":"G\u00fcl A (2005) Beh\u00e7et\u2019s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 4:81\u201383","journal-title":"Curr Drug Targets Inflamm Allergy"},{"issue":"9","key":"9788_CR83","first-page":"1544","volume":"20","author":"JL Mege","year":"1993","unstructured":"Mege JL, Dilsen N, Sanguedolce V et al (1993) Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et\u2019s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 20(9):1544\u20131549","journal-title":"J Rheumatol"},{"key":"9788_CR84","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bjo.2006.0101477","volume":"91","author":"SC Teoh","year":"2007","unstructured":"Teoh SC, Sharma S, Hogan A et al (2007) Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 91:263\u2013264","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"9788_CR85","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","volume":"149","author":"C Botsios","year":"2008","unstructured":"Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA (2008) Resistant Beh\u00e7et disease responsive to anakinra. Ann Intern Med 149(4):284\u2013286","journal-title":"Ann Intern Med"},{"issue":"1","key":"9788_CR86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00296-003-0400-6","volume":"25","author":"N D\u00fczg\u00fcn","year":"2005","unstructured":"D\u00fczg\u00fcn N, Aya\u015flio\u011flu E, Tutkak H, Aydintu\u011f OT (2005) Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Beh\u00e7et\u2019s disease. Rheumatol Int 25(1):1\u20135","journal-title":"Rheumatol Int"},{"key":"9788_CR87","doi-asserted-by":"crossref","unstructured":"Blech M, Peter D, Fischer P (2012) One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1\u03b2. J Mol Biol (in press)","DOI":"10.1016\/j.jmb.2012.09.021"},{"key":"9788_CR88","first-page":"81","volume":"11","author":"LD Church","year":"2009","unstructured":"Church LD, McDermott MF (2009) Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 11:81\u201389","journal-title":"Curr Opin Mol Ther"},{"key":"9788_CR89","unstructured":"Cantarini L, Vitale A, Borri M, Galeazzi M, Franceschini R (2012) Successful use of canakinumab in a patient with resistant Beh\u00e7et\u2019s disease. Clin Exp Rheumatol 30(3 Suppl 72):S115"},{"key":"9788_CR90","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/annrheumdis-2012-201383","volume":"71","author":"S Ugurlu","year":"2012","unstructured":"Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Beh\u00e7et\u2019s syndrome with refractory eye disease. Ann Rheum Dis 71:1591\u20131592","journal-title":"Ann Rheum Dis"},{"key":"9788_CR91","first-page":"755","volume":"12","author":"J Geiler","year":"2010","unstructured":"Geiler J, McDermott MF (2010) Gevokizumab, an anti-IL-1\u03b2 mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther 12:755\u2013769","journal-title":"Curr Opin Mol Ther"},{"issue":"4","key":"9788_CR92","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A G\u00fcl","year":"2012","unstructured":"G\u00fcl A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A (2012) Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: an open-label pilot study. Ann Rheum Dis 71(4):563\u2013566","journal-title":"Ann Rheum Dis"},{"issue":"6092","key":"9788_CR93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","volume":"324","author":"T Hirano","year":"1986","unstructured":"Hirano T, Yasukawa K, Harada H et al (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324(6092):73\u201376","journal-title":"Nature"},{"key":"9788_CR94","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","volume":"26","author":"L Kaly","year":"2012","unstructured":"Kaly L, Rosner I (2012) Tocilizumab\u2014a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 26:157\u2013165","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"7","key":"9788_CR95","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T (2010) IL-6: regulator of Treg\/Th17 balance. Eur J Immunol 40(7):1830\u20131835","journal-title":"Eur J Immunol"},{"issue":"3","key":"9788_CR96","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaci.2011.05.029","volume":"128","author":"G Geri","year":"2011","unstructured":"Geri G, Terrier B, Rosenzwajg M et al (2011) Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh\u00e7et disease. J Allergy Clin Immunol 128(3):655\u2013664","journal-title":"J Allergy Clin Immunol"},{"key":"9788_CR97","doi-asserted-by":"crossref","unstructured":"Ogata A, Tanaka T (2012) Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol. doi: 10.1155\/2012\/946048","DOI":"10.1155\/2012\/946048"},{"key":"9788_CR98","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","volume":"22","author":"T Hirano","year":"2012","unstructured":"Hirano T, Ohguro N, Hohki S et al (2012) A case of Beh\u00e7et\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 22:298\u2013302","journal-title":"Mod Rheumatol"},{"issue":"1","key":"9788_CR99","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2011.07.001","volume":"11","author":"E Miserocchi","year":"2011","unstructured":"Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V (2011) Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 11(1):35\u201339","journal-title":"Autoimmun Rev"},{"issue":"1","key":"9788_CR100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ophtha.2010.07.031","volume":"118","author":"E Miserocchi","year":"2011","unstructured":"Miserocchi E, Pontikaki I, Modorati G, Bandello F, Meroni PL, Gerloni V (2011) Rituximab for uveitis. Ophthalmology 118(1):223\u2013224","journal-title":"Ophthalmology"},{"issue":"8","key":"9788_CR101","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","volume":"50","author":"A Heiligenhaus","year":"2011","unstructured":"Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxf) 50(8):1390\u20131394","journal-title":"Rheumatology (Oxf)"},{"key":"9788_CR102","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M et al (2010) Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13:246\u2013252","journal-title":"Int J Rheum Dis"},{"key":"9788_CR103","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-008-0057-9","volume":"18","author":"S Sadreddini","year":"2008","unstructured":"Sadreddini S, Noshad H, Molaeefard M, Noshad R (2008) Treatment of retinal vasculitis in Beh\u00e7et\u2019s disease with rituximab. Mod Rheumatol 18:306\u2013308","journal-title":"Mod Rheumatol"},{"issue":"3","key":"9788_CR104","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/bjo.2009.176750","volume":"94","author":"RW Lee","year":"2010","unstructured":"Lee RW, Dick AD (2010) Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Beh\u00e7et\u2019s uveitis. Br J Ophthalmol 94(3):269\u2013270","journal-title":"Br J Ophthalmol"},{"key":"9788_CR105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/08820538.2011.588665","volume":"26","author":"NR Benitah","year":"2011","unstructured":"Benitah NR, Sobrin L, Papaliodis GN (2011) The use of biologic agents in the treatment of ocular manifestations of Behcet\u2019s disease. Semin Ophthalmol 26:295\u2013303","journal-title":"Semin Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-013-9788-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-013-9788-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-013-9788-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,14]],"date-time":"2019-07-14T08:52:14Z","timestamp":1563094334000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-013-9788-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,1]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["9788"],"URL":"https:\/\/doi.org\/10.1007\/s10792-013-9788-5","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,1]]}}}